Signal from the log
AusperBio
120 M$ · Series C · United States · Biotech
AusperBio développe des oligonucléotides antisens contre l'hépatite B chronique, une infection que les traitements actuels contiennent sans guérir. Son candidat AHB-137 est évalué en phase 3 en Chine et vise la suppression de l'antigène de surface du virus.
Verified
Announced on , logged by the watch of 28 August 2026.
- Operation
- Funding round
- Announced amount
- 120 M$
- Stage
- Series C
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Investisseur stratégique non nommé , with RA Capital Management
Provenance
Source prnewswire
Logged on 28 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.